A prospective, single-arm, phase II clinical study of Iodine 125 particle brachytherapy combined with TACE and lenvatinib and Tislelizumab for hepatocellular carcinoma with portal vein thrombosis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500106171

Enrollment

Unknown

Registered

2025-07-18

Start date

2025-03-13

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Experimental group:TACE + lenvatinib + Tislelizumab + iodine 125 particle implantation

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. age >18 years; 2. diagnosis of hepatocellular carcinoma (HCC); 3. stage BCLC-C; 4. portal vein thrombosis; 5. ECOG physical status score of 0 or 1; 6. Child-Pugh score of 5-8; 7. no previous treatment with immune checkpoint inhibitors or targeted drugs; 8. at least one intrahepatic measurable lesion

Exclusion criteria

Exclusion criteria: 1. combination of active infections, etc.; 2. with active autoimmune disease; 3. with hepatic encephalopathy, active gastrointestinal bleeding or uncontrollable ascites; 4. pregnant lactating mothers.

Design outcomes

Primary

Measure	Time frame
Objective response rate;	—

Secondary

Measure	Time frame
Progress-free survival;Overall survival;Safety;	—

Countries

China

Contacts

Public ContactYi Chen

First Hospital of Shanxi Medical University

chenyi5639@163.com+86 351 463 9773

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026